Skip to main content

Table 3 Data from HNSCC patients' serum employed to isolate circulating immune complexes.

From: MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis

Sample

Localization

Stage

Sex

Age

Differentiation

MUC1 In CIC

MUC1 in IHQ

MUC1-CT in IHQ

CIC levels (OD)

MUC1 serum levels (U/mL)

1

Larynx

I

M

52

Poorly

+

-

-

0.306

3.9

2

Larynx

III

M

64

Well

+

-

-

0.371

1.4

3

Larynx

III

M

56

Moderately

+

-

+

0.320

1.2

4

Larynx

III

M

70

Moderately

+

-

+

0.229

0.9

5

Larynx

IVA

M

58

Poorly

-

-

+

0.411

2.2

6

Larynx

IVA

M

53

Moderately

-

-

+

0.312

1.7

7

Oral Cavity

IVA

M

55

Moderately

-

+

+

0.322

4.7

8

Oral Cavity

IVA

F

29

Moderately

+

-

+

0.258

1.7

9

Oral Cavity

IVA

M

68

Moderately

+

-

+

0.323

1.1

10

Oral Cavity

IVA

M

55

Moderately

-

-

-

0.477

0.6

11

Oral Cavity

IVA

M

49

Well

-

-

+

0.403

0.7

12

Pharynx

IVA

M

56

Moderately

-

-

-

0.497

5.3

13

Pharynx

IVA

M

65

Moderately

+

-

+

0.335

1.9

14

Pharynx

IVA

M

38

Poorly

+

+

+

0.231

1.8

15

Pharynx

IVA

M

72

Moderately

-

-

-

0.473

0.4

16

Pharynx

IVB

M

61

Moderately

-

-

+

0.349

1.5

Positive/Total or mean value

    

8/16

2/16

11/16

0.351

2.0

  1. Clinical data with immunohistochemical detection and serum determination of MUC1, anti-MUC1 Abs and circulating immune complexes are depicted.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us